Athira Pharma, Inc. Common Stock (ATHA)
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Athira Pharma, Inc. Common Stock (ATHA) was listed on Nasdaq from September 18, 2020 and stopped trading under the symbol ATHA on January 12, 2026.
- Listed On
- Nasdaq
- Listed Since
- September 18, 2020
- Stopped Trading
- January 12, 2026
- Employees
- 26
About Athira Pharma, Inc. Common Stock
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Frequently asked questions
What is ATHA?
Athira Pharma, Inc. Common Stock (ATHA) was listed on Nasdaq from September 18, 2020 and stopped trading under the symbol ATHA on January 12, 2026.
Every reported institutional holder, plus insider and congressional trades in ATHA, on SentiSense.